Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Show more

Location: 1800 Sierra Point Parkway, Suite 217, Brisbane, CA, 94005, United States | Website: https://dayonebio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

648.7M

52 Wk Range

$6.08 - $16.76

Previous Close

$6.50

Open

$6.58

Volume

1,872,363

Day Range

$6.32 - $6.62

Enterprise Value

188.8M

Cash

473M

Avg Qtr Burn

-21.85M

Insider Ownership

17.03%

Institutional Own.

94.47%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.